Objective: To evaluate the nature and incidence of psychiatric and cognitive adverse events (AEs) reported with eslicarbazepine acetate (ESL) used as adjunctive treatment for refractory partial-onset seizures (POS) in adults. Methods: This was a post-hoc analysis of data pooled from three randomized double-blind, placebo-controlled trials (BIA-2093-301, -302, -304). After an 8-week baseline period, patients received placebo or adjunctive ESL 400 mg (studies 301 and 302 only), 800 mg, or 1200 mg once daily (QD) for 14 weeks (2-week titration period, 12-week maintenance period). Psychiatric and cognitive AEs were identified from individual patient data. Suicidality was also evaluated using the Columbia-Classification Algorithm of Suicide Assessment (C-CASA), or the ColumbiaSuicide Severity Rating Scale (C-SSRS). P-values were obtained using the chi-square test of independence or Fisher's exact test, without correcting for multiplicity. Results: The analysis population included 1447 patients (ESL, n = 1021; placebo, n = 426). Psychiatric treatmentemergent AEs (TEAEs) occurred in 10.8% of patients receiving ESL, and in a comparable proportion (10.3%) of patients receiving placebo (p = 0.802). However, the incidence of depression and suicidality-related TEAEs was significantly higher for ESL (7.4%) vs. placebo (3.8%) (p = 0.009). The occurrence of these TEAEs differed between treatment groups (p = 0.010), but there was no notable trend between increasing ESL dose and increasing incidence of depression and suicidality-related TEAEs. Aggression/hostility-related TEAEs occurred in b0.1% of patients taking ESL vs. 0.9% taking placebo. The incidence of cognitive TEAEs was significantly higher for ESL (7.1%) vs. placebo (4.0%) (p = 0.023); incidences of memory impairment, attention disturbance, apathy, aphasia, and bradyphrenia were higher for ESL 1200 mg than for other treatment groups. Incidences of psychiatric and cognitive serious AEs (SAEs) were 0.6% and 0.2% with ESL, and 0.5% and 0% with placebo, respectively. Psychiatric and Abbreviations: ADHD, attention deficit hyperactivity disorder; AED, antiepileptic drug; AE, adverse event; CBZ, carbamazepine; C-CASA, Columbia-Classification Algorithm of Suicide Assessment; C-SSRS, Columbia-Suicide Severity Rating Scale; ESL, eslicarbazepine acetate; LEV, levetiracetam; LTG, lamotrigine; MedDRA, Medical Dictionary for Regulatory Activities; OXC, oxcarbazepine; POS, partial-onset seizures; QD, once daily; SAE, serious adverse event; SMQ, standardized MedDRA queries; TEAE, treatment-emergent adverse event; VPA, valproic acid.
Introduction
Psychiatric illness and cognitive abnormalities are common comorbidities in patients with epilepsy [1, 2] . In addition, most antiepileptic drugs (AEDs) carry a risk of psychiatric adverse events (AEs; including hyperactivity, agitation, irritability, aggression, depression, and psychosis) and might also have the potential to induce suicidal ideation and behavior; the risk varies between AED classes [3] [4] [5] [6] . AEDs can also have a detrimental effect on cognitive function, which can lead to impairments in learning, driving ability, and memory [6, 7] .
Eslicarbazepine acetate (ESL, Aptiom®, Sunovion Pharmaceuticals Inc., Marlborough, MA; Zebinix®, BIAL -Portela & C a , S.A., S. Mamede do Coronado, Portugal) is a once-daily (QD) oral AED for the treatment of partial-onset seizures (POS).
Three randomized, double-blind, phase III, placebo-controlled studies (BIA-2093-301, 302, and 304) examined the efficacy and safety of ESL as adjunctive therapy in adults with treatment-refractory POS [8] [9] [10] . Treatment with ESL 800 mg QD resulted in a statistically significant reduction in seizure frequency in two of the three studies, while ESL 1200 mg QD significantly reduced seizure frequency in all three studies [8] [9] [10] . The overall incidences of treatment-emergent AEs (TEAEs) and TEAEs leading to discontinuation were higher at higher ESL doses; the overall incidence of serious TEAEs with ESL was 5.3% versus 2.8% with placebo, and TEAEs leading to discontinuation occurred in 17.5% of patients taking ESL versus 6.6% of patients taking placebo [11] .
This post-hoc analysis of data pooled from these three studies examines the nature and incidence of psychiatric AEs, and of AEs potentially related to changes in cognitive function, reported during treatment with adjunctive ESL.
Methods

Standard protocol approvals, registration, and patient consents
The three studies (BIA-2093-301 [NCT00957684]; -302 [NCT00957047]; and -304 [NCT00988429]; registered at ClinicalTrials. gov) were undertaken at centers in 35 countries between 2004 and 2012, in accordance with the principles of the Declaration of Helsinki, the International Conference on Harmonisation guidelines and all national, state, and local laws of the pertinent regulatory authorities. Approval was received from the relevant independent ethics committees/institutional review boards; written informed consent was obtained from all patients.
Study design
The study designs (including sample size determination), standard protocol approvals, registrations, and patient consents for studies 301, 302, and 304 have been reported previously [8] [9] [10] . Following an 8-week baseline period, patients were randomized equally to receive placebo or ESL 400 mg (studies 301 and 302 only), 800 mg, or 1200 mg tablets orally QD for 14 weeks (2-week titration period followed by a 12-week maintenance period), followed by a 2-week tapering-off period (studies 301 and 304) or abrupt discontinuation of treatment (study 302). Study treatment was added to continued stable doses of baseline AEDs.
Patients
Patients aged 16-75 years with POS not adequately controlled by one to two (studies 301 and 304) or one to three (study 302) AEDs were eligible for inclusion. The use of oxcarbazepine (OXC) was not allowed due to similarities between OXC and ESL metabolites. Further details of the inclusion and exclusion criteria for these trials have been published previously [8] [9] [10] . Patients with a history of suicide attempts or major psychiatric disorders, including schizophrenia, were excluded from the studies.
Assessment of TEAEs
Individual patient data from studies 301, 302, and 304 were pooled and analyzed, and patients with psychiatric or cognitive TEAEs were identified; investigators recorded TEAEs and were asked to assess them in terms of severity (mild, moderate, severe) and seriousness (serious, nonserious). A serious AE (SAE) was classified as any TEAE that: resulted in death; was life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity; was a birth defect; or was another medically important condition. TEAEs were categorized using the Medical Dictionary for Regulatory Activities (MedDRA) v13.1.
Psychiatric TEAEs were identified as those within the System Organ Class "Psychiatric Disorders". Psychiatric TEAEs (including signs and symptoms) from the three trials were evaluated. TEAEs were also identified by clinical audit of investigator records and case report forms, and by review of patient narratives and SAE reports (Council for International Organizations of Medical Sciences forms).
Depression and suicidality TEAEs were identified by standardized MedDRA queries (SMQs; validated sets of MedDRA TEAEs used to identify specific safety topics of interest) for "depression" (excluding "suicide" and "self-injury") and "suicide/self-injury" (TEAEs with the Preferred Terms "suicide", "suicidal", or "self-injury"). Suicidality was also evaluated retrospectively by blinded review using the ColumbiaClassification Algorithm of Suicide Assessment (C-CASA) (studies 301 and 302), and prospectively using the Columbia-Suicide Severity Rating Scale (C-SSRS) to assess suicidal behavior after the baseline period (study 304) [12] . The number of patients with C-CASA scores of one to four (suicidal behavior/ideation) or seven (nonsuicidal self-injurious behavior) was determined for each treatment group, and the number of patients with C-SSRS ratings of "any suicidal behavior" or "worsening in suicidal ideation" was recorded separately.
Hostility/aggression-related TEAEs were identified by a narrow SMQ for "hostility/aggression".
The following searches were used to identify cognitive TEAEs: SMQs for "hostility/aggression" and "psychosis and psychotic disorders"; any investigator-reported TEAEs of "memory impairment", "amnesia", "bradyphrenia", "psychomotor retardation", "speech disorder", "aphasia", "disturbance in attention", or "change in sustained attention"; and any investigator-reported TEAE in the high level term of "mental impairment" (excluding dementia and memory loss) or "cognitive and attention disorders and disturbances not elsewhere classified". Searches used TEAEs from the clinical database, and additional potential TEAEs identified during reviews of subject records.
The safety population (patients who received ≥1 dose of study drug after randomization) was used for these analyses.
Statistical analysis
Numbers and percentages of patients with TEAEs were summarized by treatment group. P-values for incidence differences between groups were obtained using the chi-square test of independence, or Fisher's exact test (for TEAEs with low incidence i.e., occurring in fewer than 5 patients), without correcting for multiplicity. Logistic regression was used to examine the ESL-dose effects for cognitive and psychiatric TEAEs. Time to first onset of a TEAE was the number of days between first dose and the TEAE occurrence. TEAE duration was the number of days between onset and end-date. Comparisons between durations and times to first onset were performed using non-parametric Wilcoxon rank sum tests.
Results
Patients
The safety population included 1447 patients (placebo, n = 426; ESL 400 mg, n = 196; 800 mg, n = 415; 1200 mg, n = 410; total ESL, n = 1021).
Patient demographic and baseline characteristics have been previously reported, and were similar between treatment groups [8] [9] [10] . Median age was 37-38 years (range: 16-75 years); 49% of patients were male, and 80% were Caucasian. Overall, 28% of patients were receiving one baseline AED and 72% were receiving two or more. The most frequently used concomitant AED was carbamazepine (CBZ; 50% of 
Note: patients may have had N1 TEAE/SAE; patients with N1 incidence of a specific TEAE/SAE were counted only once. Similarly, N1 TEAE leading to discontinuation of study medication may have occurred in some patients. ADHD: attention deficit hyperactivity disorder; ESL: eslicarbazepine acetate; SAEs: serious adverse events; TEAEs: treatment-emergent adverse events. a For psychiatric TEAEs occurring in ≥0.5% of patients in any ESL dose group. b For psychiatric TEAEs leading to discontinuation of study medication in N1 patient taking ESL. patients), followed by lamotrigine (LTG; 24%), valproic acid (VPA; 22%), and levetiracetam (LEV; 18%).
Psychiatric AEs
Psychiatric TEAEs
Incidences of reported psychiatric TEAEs are shown in Table 1 ; psychiatric TEAEs occurred in 10.8% of patients taking ESL (400 mg, 10.2%; 800 mg, 11.3%; 1200 mg, 10.5%) and in 10.3% of patients taking placebo (p = 0.802). The occurrence of psychiatric TEAEs was not related to ESL dose (p = 0.894). The most frequent psychiatric TEAEs in patients taking ESL were depression (2.4%), insomnia (2.0%), and anxiety (1.7%). There was no clear or consistent relationship between ESL dose and incidence of any individual psychiatric TEAE. Indeed, six psychiatric TEAEs occurred in one patient each in the ESL 400 mg group, but in no other treatment groups. Furthermore, 12 of the 23 TEAEs that occurred in ≥ 0.5% of patients in any ESL dose group were not seen in the ESL 1200 mg dose group.
Most psychiatric TEAEs were mild or moderate in severity (Table 1 ). Psychiatric SAEs occurred in relatively few patients (ESL, 0.6%; placebo, 0.5%; p = 1.0); no psychiatric SAEs occurred in patients taking the highest ESL dose (1200 mg), with the greatest overall incidence in the ESL 400 mg dose group (1.5%), where ten separate SAEs occurred in three individuals (Table 1) . Psychiatric TEAEs leading to discontinuation occurred in 1.9% of patients taking ESL and in 0.7% of those taking placebo (p = 0.155) ( Table 1) .
The median time to first onset of psychiatric TEAEs and the median duration of these TEAEs are shown in Fig. 1 . Time to onset of psychiatric TEAEs appeared to be shortest for ESL 400 mg (compared with placebo, ESL 800 mg, and ESL 1200 mg), whereas the median duration of these TEAEs appeared to be longer for ESL 400 and 1200 mg than for ESL 800 mg and placebo. Therefore, the ESL 800 mg dose group had the longest time to onset and the shortest duration of psychiatric TEAEs. Neither time to onset nor duration of psychiatric TEAEs were significantly different between ESL and placebo (p = 0.838 and p = 0.288, respectively).
Depression and suicidality-related events
The overall incidence of depression and suicidality-related TEAEs was significantly higher for patients receiving ESL (7.4%) than for those receiving placebo (3.8%; p = 0.009) ( Table 2 ). In addition, the occurrence of depression and suicidality-related TEAEs differed between treatment groups (p = 0.010); the incidence of these TEAEs was lower in the placebo and ESL 800 mg groups than in the ESL 400 mg and 1200 mg groups. Note that as "psychiatric TEAEs" and "depression and suicidality TEAEs" were identified independently (see Methods), certain TEAEs (e.g., depression) were included in both data sets. Depression was the only depression and suicidality TEAE to affect N2% of patients taking ESL, and was also reported for N2% of patients taking placebo (2.4% and 2.1%, respectively).
Depression and suicidality-related SAEs occurred in two patients taking ESL (depression in one patient, suicide attempt and suicidal ideation in the other), neither of whom were taking the highest ESL dose (1200 mg) (reported in Table 1 , as they were also identified as "psychiatric" SAEs as part of the previous analysis). No depression and suicidality-related SAEs occurred in the placebo group; however, SAE incidence was not significantly higher with ESL versus placebo (p = 1.0). Although 13 patients taking ESL had a depression/suicidalityrelated TEAE that led to discontinuation, only three specific TEAEs occurred in ≥2 patients taking ESL (depression [4 patients], disturbance in attention [2 patients], and hypersomnia [2 patients]; Table 2 ). The incidence of depression and suicidality-related TEAEs leading to discontinuation was not significantly different between the placebo (0.2%) and ESL (1.3%) groups (p = 0.079).
The median time to onset of depression and suicidality-related TEAEs was slightly shorter for patients taking ESL (15 days) than for those taking placebo (17 days), and the median duration of these events was slightly longer for ESL (29 days) than for placebo (25 days).
Assessments of suicidal ideation and behavior (C-CASA ratings and C-SSRS scores) are shown in Table 3 ; there was no clear difference in rates of suicidal ideation and behavior between the ESL and placebo groups.
Aggression/hostility-related TEAEs
The overall incidence of aggression/hostility-related TEAEs was b0.1% in patients taking ESL and 0.9% in patients taking placebo. 'Aggressive behavior' was reported in one patient taking placebo, 'aggression' in two patients, one taking placebo, the other taking ESL 400 mg, 'temper tantrum' in one patient taking placebo, and 'aggravated aggression' in one patient taking placebo; these events comprise the 5 reports of 'aggression' shown in Table 1 .
Cognitive TEAEs
The incidence of cognitive TEAEs was significantly higher for patients receiving ESL (7.1%) than for those receiving placebo (4.0%; p = 0.023), but no single cognitive TEAE occurred in more than 1.5% of patients taking ESL (Table 4 ). The occurrence of cognitive TEAEs was not clearly related to ESL dose (p = 0.070). The most frequently reported cognitive TEAEs with ESL were irritability, memory impairment, and attention disturbance. Incidences of memory impairment, attention disturbance, apathy, aphasia, and bradyphrenia (slowness of thought) were higher for ESL 1200 mg than for the lower doses. The incidence of cognitive SAEs with ESL was 0.2%; one patient taking ESL 400 mg had six cognitive SAEs: abnormal behavior, aggression, logorrhea, paranoia, psychotic disorder, and abnormal thinking (all are shown in Table 1 as they were also identified as "psychiatric" SAEs); the cognitive SAE of amnesia occurred in one patient taking ESL 1200 mg; no patients in the placebo group had an SAE. However, SAE incidence was not significantly higher with ESL versus placebo (p = 1.0). The incidence of cognitive TEAEs leading to discontinuation was also numerically higher for patients taking ESL (1.4%) than for those taking placebo (0.5%), but the difference was not statistically significant (p = 0.173) ( Table 4) .
The median time to first onset of cognitive TEAEs and the median duration of these events are shown in Fig. 2 . The time to onset of cognitive TEAEs was shortest with ESL 800 mg, whereas the median duration of these TEAEs appeared to be dose-related; cognitive TEAE duration was numerically lower for ESL 400 mg and 800 mg than for ESL 1200 mg. The difference between placebo and ESL was not significantly different for time to, or duration of, cognitive TEAEs (p = 0.881 and p = 0.441, respectively).
Incidence of psychiatric and cognitive TEAEs according to baseline AED use
Incidences of psychiatric and cognitive TEAEs according to baseline use of CBZ, LTG, VPA, and LEV, all used concomitantly by ≥ 15% of patients, are shown in Table 5 . The overall incidence of cognitive TEAEs appeared to be lower for patients taking CBZ during the baseline period than for those who were not (ESL: +CBZ 7.6%, −CBZ 10.9%, p = 0.074; placebo: +CBZ 3.0%, −CBZ 7.5%, p = 0.044). A similar, although less marked, trend was observed for psychiatric TEAEs. In the placebo Table 3 Suicidal ideation and behavior (based on C-SSRS ratings and C-CASA scores). Note: These data were not included in the TEAE tabulations, and consequently some patients had C-SSRS findings without having reported TEAEs. C-CASA: Columbia-Classification Algorithm of Suicide Assessment; C-SSRS: Columbia-Suicide Severity Rating Scale; ESL: eslicarbazepine acetate; TEAE: treatment-emergent adverse event.
a C-CASA codes 1-4 represent suicidal behavior, and code 7 represents self-injurious behavior without suicidal intent. Note: patients may have had N1 TEAE; patients with N1 incidence of a specific TEAE were counted only once. Similarly, N1 TEAE leading to discontinuation of study medication may have occurred in some patients. ESL: eslicarbazepine acetate; TEAEs: treatment-emergent adverse events. Note: patients may have had N1 TEAE; patients with N1 incidence of a specific TEAE were counted only once. Similarly, N1 TEAE leading to discontinuation of study medication may have occurred in some patients. ESL: eslicarbazepine acetate; TEAEs: treatment-emergent adverse events. a For cognitive TEAEs occurring in ≥1 patient receiving ESL.
Median time to cognitive TEAE (days)
group, the overall incidence of cognitive TEAEs was higher for patients taking LTG during baseline than for those who were not (+LTG 8.3%, −LTG 4.4%; p = 0.118); the opposite effect was observed in the placebo group +/− baseline VPA (+VPA 2.1%; −VPA 6.3%; p = 0.127). In the ESL group, however, there was very little difference in the incidence of cognitive TEAEs between +/−LTG and +/−VPA. The incidence of cognitive TEAEs was significantly higher with ESL versus placebo in the − LTG group (p = 0.038), but not in the + LTG group (p = 0.336). The overall incidence of psychiatric TEAEs was lower for patients who were taking VPA at baseline than for those who were not (ESL: +VPA 6.9%, −VPA 11.8%, p = 0.037; placebo: +VPA 6.3%, −VPA 11.5%, p = 0.145). In contrast, the overall incidence of psychiatric TEAEs was higher for patients taking baseline LEV versus those who were not (ESL: +LEV 13.6%, −LEV, 10.2%, p = 0.178; placebo: +LEV 13.5%, −LEV 9.5%, p = 0.272). The overall incidence of cognitive TEAEs was also higher for +LEV versus −LEV (ESL: +LEV 11.9%, −LEV 8.6%, p = 0.169; placebo: + LEV 13.5%, − LEV 3.3%, p = 0.0001); cognitive TEAE incidence was significantly higher with ESL versus placebo in the − LEV group (p = 0.022), but not in the +LEV group (p = 0.374). There were no other significant differences in psychiatric and cognitive TEAE incidences between ESL and placebo, in any of the AED groups.
Discussion
In this pooled analysis of data from 1447 patients in three phase III studies of adjunctive ESL, the incidences of reported cognitive and psychiatric TEAEs (including depression and suicidality) were examined, as well as additional measures of suicidal ideation and behavior. The results from these post-hoc analyses will contribute toward our understanding of the potential psychiatric and cognitive impact of add-on ESL in adults with POS.
Psychiatric AEs are relatively common in patients taking AEDs. For example, in an outpatient study at the Columbia Comprehensive Epilepsy Center, chart review identified that AED-related psychiatric/ behavioral side effects were reported for 16% of patients who began taking a 'newer' AED (e.g., gabapentin, LTG, LEV, vigabatrin, felbamate, OXC, tiagabine, topiramate, or zonisamide) as an add-on or as monotherapy [13] . It is of note that patients with a significant psychiatric history (e.g., schizophrenia, suicide attempts, or major psychiatric disorders) were excluded from the current studies. However, some patients may have had a psychiatric condition on entering these trials, as patients on stable regimens of antidepressants were permitted to participate. Furthermore, given the relatively high incidence of psychiatric illness in patients with epilepsy [1] , it is possible that 'latent' psychiatric symptoms could emerge during the studies. However, this is somewhat unlikely in typical trials of adjunctive AEDs, where patients generally have a mean duration of epilepsy of~20 years.
In the current analysis, the overall incidence of psychiatric TEAEs was comparable between ESL and placebo (ESL, 10.8%; placebo, 10.3%) with no apparent dose dependence, suggesting that the psychiatric TEAEs reported in this study were not related to ESL use, but were likely caused by other factors. Depression was the most frequent psychiatric TEAE, which occurred in similar proportions of patients in the ESL and placebo treatment groups (ESL, 2.4%; placebo, 2.1%). The incidence of Table 5 : Note: patients may have had N1 TEAE; patients with N1 incidence of a specific TEAE were counted only once. AED: antiepileptic drug; ESL: eslicarbazepine acetate; CBZ: carbamazepine; TEAEs: treatment-emergent adverse events. a For TEAEs with an incidence ≥2% in any ESL dose group within either the +AED or −AED subgroups. b For AEDs used by ≥15% of the study population. c The cognitive TEAE "agitation" is also considered a psychiatric TEAE and is reported in the psychiatric TEAEs section. d The cognitive TEAEs "abnormal behavior", "aggression", "logorrhea", "paranoia", "psychotic disorder", and "abnormal thinking" are also considered psychiatric TEAEs, and are reported in the psychiatric TEAEs section.
psychiatric SAEs (ESL, 0.6%; placebo, 0.5%) was also comparable between ESL and placebo, whereas psychiatric TEAEs leading to discontinuation were more frequent with ESL than with placebo (ESL, 1.9%; placebo, 0.7%). There was no apparent dose dependence for SAEs or TEAEs leading to discontinuation. Furthermore, no patients taking the highest ESL dose (1200 mg) had a psychiatric SAE; the incidence of psychiatric SAEs was in fact highest in the 400 mg dose group (1.5%; 800 mg, 0.7%; placebo, 0.5%). The incidence of psychiatric TEAEs leading to discontinuation was also highest in the 400 mg dose group (2.6%; 800 mg, 1.0%; 1200 mg, 2.4%; placebo, 0.7%). The ESL 800 mg group had both the longest time to onset and the shortest duration of psychiatric TEAEs. Overall, the incidence of psychiatric TEAEs in the current analysis does not appear to be markedly different to rates observed in phase III trials of other third-generation AEDs (namely perampanel, brivaracetam and lacosamide) [14] [15] [16] [17] [18] [19] . The overall incidence of psychiatric TEAEs was lower in patients taking VPA and higher in patients taking LEV at baseline than for those who were taking other AEDs. This may reflect the mood stabilizing properties of VPA [20] and is consistent with previous analyses showing that LEV was associated with psychiatric side effects [21, 22] . However, it is notable that patients were on a stable LEV dose at study entry and therefore, presumably, psychiatric side effects occurring before study entry were not thought to warrant dose adjustment or discontinuation of LEV. Overall, in the current study, psychiatric TEAE incidence did not appear to be related to use of ESL, irrespective of baseline concomitant AED use. In a previous analysis, some nonpsychiatric/ cognitive TEAEs (e.g., dizziness, diplopia, vomiting, and nausea) were reported more frequently in patients taking ESL in combination with CBZ than in those not taking concomitant CBZ [23] . However, in the current analysis, the incidence of psychiatric or cognitive TEAEs was not elevated in patients taking CBZ at baseline compared with those who did not take CBZ; indeed, the incidence of psychiatric/cognitive TEAEs was lower in the group of patients who were taking CBZ at baseline.
The overall incidence of depression and suicidality-related TEAEs was greater for patients taking ESL than for those taking placebo (p b 0.01); the occurrence of these TEAEs differed between treatment groups (p = 0.010), but there was no notable trend between increasing ESL dose and increasing incidence of these TEAEs. Time to first onset of depression and suicidality-related TEAEs was numerically shorter, and duration of these TEAEs was numerically longer for ESL than for placebo. It is of note that 13 of the 19 patients with psychiatric TEAEs leading to discontinuation discontinued due to depression/ suicidality-related TEAEs. However, there was no difference in rates of suicidal ideation and behavior (based on C-CASA ratings and C-SSRS scores) between the ESL and placebo groups.
Hostility/aggression TEAE data from a pooled analysis of three phase III studies of perampanel resulted in the warning for potential serious psychiatric and behavioral reactions present in the perampanel prescribing information [14, 24] . We, therefore, conducted a comparable analysis of ESL data here, where we found that hostility/aggression TEAEs occurred in only one patient taking ESL (b0.1%, in the 400 mg dose group), compared with 4 patients taking placebo (0.9%), with no cases of actual homicidal ideation or threats.
A review of reports based on clinical studies in epilepsy patients examined the cognitive impact of AEDs and concluded that among AEDs of the dibenzazepine carboxamide drug class, CBZ has the potential to induce mild, but sometimes significant, cognitive effects, whereas, OXC is associated with only minor cognitive difficulties [25] . In the current analysis, the incidences of cognitive TEAEs and SAEs with adjunctive ESL (the newest member of the dibenzazepine carboxamide AED class) were low (7.1% and 0.2%, respectively), despite the fact that all patients were taking concomitant AEDs, some of which are known to impair cognitive function, particularly when used as polytherapy [7] . Cognitive TEAEs were significantly more frequent, however, in the total ESL group than in the placebo group (p b 0.05). A separate analysis of cognitive TEAEs was conducted by the US Food and Drug Administration (FDA) and contributed to the current ESL US labelling; the analysis concluded that the incidences of memory impairment, attention disturbance, amnesia, aphasia, speech disorder, bradyphrenia, and psychomotor retardation were all dose dependent [26] (see Table 4 ). The FDA analysis also identified confusional state and disorientation as dose-dependent cognitive TEAEs. A previous analysis found that dizziness was the most frequent TEAE leading to discontinuation in patients taking adjunctive ESL in the current studies, occurring in 6.1% of patients [11] . In comparison, psychiatric and cognitive TEAEs leading to discontinuation occurred in relatively few patients (1.9% and 1.4%, respectively).
A limitation of this analysis is that statistical comparisons of psychiatric and cognitive TEAE incidences were conducted retrospectively. pValues were calculated using the chi-square test of independence or the Fisher's exact test; however, corrections for multiplicity were not applied, and so the results should be interpreted with caution. In addition, with the exception of the C-SSRS and C-CASA assessments, the data reported here are based solely on TEAE reporting by patients/caregivers and by reviews of patient records. Additional studies using a range of psychiatric and cognitive assessments, and with prospectively planned psychiatric and cognitive endpoints, would be valuable to further elucidate the relationship between ESL use and psychiatric and cognitive outcomes. In addition, evaluation of the incidence of psychiatric and cognitive events with ESL monotherapy would help to determine the extent to which the events observed in this analysis were influenced by concomitant AEDs.
Overall, this analysis of data from three phase III trials of adjunctive ESL showed that there was no notable difference in incidence of psychiatric TEAEs between the three ESL dose groups (400 mg, 800 mg, and 1200 mg) and placebo. Although the overall incidences of depression/suicidality and cognitive TEAEs were greater with ESL than with placebo, incidences of individual TEAEs were low and led to few study discontinuations.
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